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I. INTRODUCTION 
Malignant melanoma (MM) is a multifactorial cancer 
with identified genetic and environmental predisposing 
factors. Prevalence rates and gene-environment 
interactions vary along geographical locations upon 
latitude. Major environmental predisposing factor is 
ultraviolet (UV) radiation. Next to UVB, the significance 
of UVA is also emerging based on epidemiologic data 
and also by findings on fibroblasts showing that there are 
weaker DNA damage response mechanisms after UVA 
than after UVB. Other extrinsic predisposing factors such 
as electromagnetic radiation, ionization radiation or 
firefighters’ environment are also characterized among 
many others. In immunosuppressed status (e.g. organ 
transplant recipients: OTR) MM risk may be elevated by 
3-8-fold.  
Genetic factors, especially in multiple primary melanoma 
(MPM) patients and in familial MM aggregations are of a 
great importance. CDKN2A and CDK4 are high-
penetrance high risk genes. Melanocortin 1 receptor 
(MC1R) gene variants confer an intermediate risk to MM. 
MC1R ‘R’ variants (R151C, I155T, R160W, D294H) are 
in strong association with a phenotype of red hair and 
3 
 
fair-, UV sensitive skin; in contrast with the ‘r’ variants 
(V60L, V92M, R163Q) whose role in this phenotype is 
much weaker. MM risk is associated at most by the ‘R’ 
variants, albeit the significance of ‘r’ variants, moreover 
irrespectively of the type-, the number of carried variants 
also influences the risk to MM. MC1R variant 
frequencies show geographical differences. In 
microphtalmia-associated transcription factor (MITF) a 
germline point mutation (p.E318K) has been verified as 
an intermediate risk factor for MPM, familial MM, and 
for MM and renal cell cancer (RCC) co-occurrence.  
MM survivors are at an increased risk of 
developing other malignancies, most frequently 
subsequent MM; however non-melanoma skin cancer 
(NMSC) mainly basal cell cancer (BCC), pancreatic 
cancer (PaC), and breast cancer occurs also at a higher 
rate among them. Furthermore as associated malignancy 
MM is also reported in a number of cancer predisposing 
syndromes, like in Breast-ovarian cancer syndrome 
(BRCA1 and BRCA2), and rarely in PTEN hamartoma 
tumor syndromes (PHTS), Cowden syndrome (CS).  
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II. AIMS 
As no genetic data was available about the major MM 
predisposing gene mutations among Hungarian MM 
(MPM) patients so far, our aim was to analyze: 
II.1. MPM patients (MPM study) by 
a. Collecting clinicopathological features, 
including patients’ phenotypes, medical history, family 
history of malignancies; MPMs’ characteristics with 
detailed histology and disease course with outcome; 
b. Germline sequence analysis of the major MM 
predisposing genes: CDKN2A, CDK4, MC1R, and MITF 
E318K; and further analysis of possible associations 
between available clinical, pathological and genetic data 
focused on MC1R variants using statistical methods. We 
also discussed a comparison of our MC1R variant 
frequencies and distributions to other countries’ results.  
c. Analysis of MC1R variant status regarding ‘r’ 
carriers (00, r0, rr) and ‘R’ carriers (R0, rR, RR), and to 
see whether these genotypes influence any of the clinical 
or pathological characteristics of MPM patients.  
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II.2. Unique MM-associated cases  
During patient care and data analysis, some patients 
presented with unique clinical course and highly positive 
medical -, and family history of benign and malignant 
tumors. In three unique MM-related cases we separately 
obtained clinical exploration of the detected tumor 
constellations and pedigrees together with  
a. sequence analysis of the most suspicious genes  
b. discussion of the relevant etiological factors 
including the identified genetic results, documented 
environmental factors, and further suspicious, herein not 
sequenced genetic events.  
III. METHODS 
III.1. Clinical data, patients’ characteristics 
III.1.1. MPM study 
From patients diagnosed with primary MM at 
Semmelweis University Department of Dermatology 
Venereology and Dermatooncology in an 11-year long 
period, 108/1855 developed subsequent MMs (5.8%); 43 
participated in the genetic studies. They developed 
altogether 106 MMs (with an average of 2.47 per capita). 
Mean follow-up time was: 6.7 (0-34.2) years. Besides the 
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routinely recorded data of medical self-, and family 
history, we also included pigmentation phenotype, 
approximate number of common and dysplastic nevi, 
smoking habit and occupation. Routine MM histologic 
parameters and disease course with propagations, 
treatments and MM-related deaths were also 
documented.  
III.1.2. Unique MM-associated cases  
III.1.2.1. Two cancer prone families  
Family A and B with two common offspring also with 
early onset malignancies have been examined.  
In family A, with many heavy smokers and firefighters, 
two non-twin brothers (one of them is index person) both 
had a unique constellation of four similar primary 
malignant tumors: MPMs (2 each), BCCs, PrC and LC. 
Furthermore within family A, LC and neural crest tumors 
occurred more times, while PaC, RCC, and gastric cancer 
incidentally. Index persons’ wife was member of family 
B that was highly positive for PaC in a dominantly 
inherited manner. One of their offspring had early onset 
RCC, while the other died at age of 37 at PaC.  
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III.1.2.2. Six primary MMs  
We analyzed a 59 year old female renal OTR patient, 
who developed six primary MMs under 7 years of 
immunosuppressive therapy. She had MM vulnerable 
cutaneous pigmentation characteristic (red hair, fair 
skin), a harmful sun tanning habit for years and bad 
compliance regarding dermatological follow-ups. Despite 
the revision of her immunosuppressive therapy after the 
4th MM to a more favorable combination in terms of 
malignant tumor development (tacrolimus to sirolimus), 
she further developed two MMs and deceased of MM 
propagation one year later.  
III.1.2.3. MM and phenotype suggesting PHTS/CS:  
We examined a female patient from a cancer prone 
family (LC, BCC, uterine cancer) who presented with 
significant body deformities (severe scoliosis, skull 
hyperostosis, dolichocephaly, disproportionate 
overgrowths and hemihypertrophies of certain body areas 
with atrophies of other sites) and the following 
diversified oncological history: lentigo maligna, verified 
breast cancer, myoma uteri, thyroid and parathyroid 
adenomas, lipomas, connective tissue nevi together with 
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suspicious RCC and genitourinary malformations raising 
the possibility of PHTS, especially of CS.  
 
III.2. Mutation analysis  
Sanger sequencing: DNA was isolated from peripheral 
lymphocytes (Roche Magna Pure System) and in some 
cases from formalin fixed paraffin embedded (FFPE) 
tissue sections (Qiagen). For PCR amplification primers 
were either obtained from previous publications, or self-
designed. Quality and quantity of PCR reaction have 
been checked with agarose gel electrophoresis on 2% 
agarose gel and GelGreen® (Biotium) staining. 
Enzymatic system (ExoShap-IT, USB) was used for 
purification of PCR products that was followed by 
sequencing reaction (BigDye Terminator v3.1 Cycle 
Sequencing Kit, Abi) and purification with gel filtration 
technology (NucleoSEQ, Macherey-Nagel GmbH). 
Finally Sanger sequencing in both directions was 
obtained using ABI PRISM 3100 Genetic Analyzer. 
Sequence results were visualized in FinchTV Softver, 
than were compared to the actual NCBI reference 
sequences. The following selected genes were analysed.  
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In the MPM study all patients have been genotyped for 
the whole coding regions with extensions to either ends, 
and exon intron boundaries of CDKN2A, MC1R together 
with exon 2 of CDK4 and MITF E318K (in exon 10). 
Regarding Unique MM-associated cases, in all the three 
cases the MM predisposing genes have been genotyped. 
Additionally: In the Two cancer prone families in 
certain family members hot spot containing fractions of 
BRCA 1 (exon 2, segments of exons 11 and 20) and of 
BRCA2 (segment of exon 11) were sequenced; while in 
some members the whole genes of BRCA1 and BRCA2, 
and PTEN gene were genotyped.  
In the OTR with six primary MMs the whole coding 
PTEN gene has been genotyped.  
In the case of MM and phenotype suggesting 
PHTS/CS SDHB and SDHD have been genotyped.  
 
Mutation verification and control analysis were 
obtained using locus specific restriction endonuclease 
enzymes: MC1R D117G with PsyI (Tth111I) (200 
alleles); MITF V320A with BsrBI (MbiI) (100 alleles) 
(both Fermentas Life Science).  
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III.3. Statistical methods 
Comparisons of continuous variables between groups in 
MPM study were performed using independent Student’s 
t-test. Categorical variables were compared using the 
Chi-square test or the Fisher-exact test whichever 
appropriate. The levels of significance were set to 
p<0.05.  
IV. RESULTS 
IV.1. Results of MPM study  
IV.1.1. Clinicopathological attributes 
Among the 43 MPM patients, the mean age at initial 
diagnosis was 61 years, which was significantly lower in 
women than in men (55.3 versus 65.4 years; p=0.016) 
and decreased with i) the history of other malignancy, ii) 
family history of MM and iii) higher final MM number. 
Family history of MM was positive in 4 patients (9.3%).  
Second MMs were observed synchronously in 
49% (21/43) of the patients. Phenotype with more than 
20 common nevi or any dysplastic naevus was presented 
in 51% of patients; they had significantly more MMs (2.8 
versus 2.4MMs; p=0.026). Twenty patients (47%) had 
the first and second MMs on the same body site. More in 
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situ tumors were observed among the second (37%)-, or 
subsequent MMs (25%) than among first MMs (9%). 
Superficial spreading MM was the most common subtype 
(60.4%), while nodular MM occurred only in four cases 
(3.8% of all MMs). First MMs exhibited significantly 
thicker Breslow (2.16 versus 1.16 mm; p=0.013) than 
subsequent ones.  
Subsequent primary malignancies among MPM patients: 
Of the 43 MPM patients, 18 (42%) had non-MM tumors 
from which 83% had cutaneous, 17% extra-cutaneous, 
while 28% had both.  
 
IV.1.2. Genetic results: 
CDKN2A: Two out of 43 MPM patients (4.7%) had 
CDKN2A mutations (c.296G>C-p.R99P and c.206A>G-
p.E69G). The well-known c.-191 G>A SNP was present 
in 88.3% of MPM patients. In the 3’UTR, SNPs c.*29 
C>G was observed in eleven patients (25.6%) while the 
c.*69 C>T in 7 (16.3%) The p.A148T SNP was carried 
only by 2 patients (4.6%).  
CDK4: None of the patients carried any of the previously 
described mutations (R24H, R24C).  
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MITF: The c.1075G>A-p.E318K mutation was not 
detected in any of our patients. We identified the SNP 
c.1082T>C-p.V320A (rs2055006) in the same exon in 
one patient, but not in 50 healthy controls.  
MC1R: Nine different variants (8 non-synonymous and 1 
synonymous) were detected in 37/43 (86%) patients. The 
overall allele frequency was 30% for ‘r’ variants and 
33% for ‘R’ variants. The most common variant was 
R151C (30%). One novel non-synonymous variant 
(c.350A>G-p.D117G) was identified in one MPM patient 
but not in 100 healthy controls. The R163Q was observed 
in 16.2% of patients with an allele frequency of 8.1%.  
IV.1.3. Analysis of MC1R variant status 
By comparing clinicopathological features of MC1R ‘R’ 
and ‘r’ carrier patients, ‘R’carriers were more prone to 
develop non-melanoma malignancies and multiple BCCs. 
Regarding MM histology, we found in ‘R’carriers a non-
significant association with more i) invasive second 
MMs, ii) ulcerated first MMs, iii) and non-ulcerated 
second MMs, but correlated significantly with tumor 
infiltrating lymphocytes (TILs) in second MMs (67 
versus 27%; p=0.035). Regression or mitotic rate showed 
no considerable differences in ‘R’ and ‘r’carriers. 
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Although propagation and death were more frequent 
among ‘R’carriers, 5-year overall survival showed no 
signicant difference.  
 
IV.2. Results of Unique MM-associated cases  
IV.2.1. Two cancer prone families 
In family A, index person carried a germline CDKN2A 
mutation (p.R99P) that was segregated also to his 
offspring with early onset fatal PaC at somatic level in 
PaC sample. The index person also carried two MC1R 
‘r’variants (V60L and V92M) and a synonymous variant 
(T314T). He also harbored a number of SNPs along 
CDKN2A (c.-191 G>A, c.*69 C>T), PTEN (c.80-96 
A>G, c.1026+32 T>G), and BRCA1 (c.1067 A>G; 
p.Q356R) genes. In family B, we found no mutations, but 
number of SNPs in CDKN2A (c.-191 G>A, c.193+174  
A>G), in BRCA1 (c.2311 T>C; p.L771L) and in BRCA2 
(c.-26 G>A, c.631+183 T>A, c.3396 A>G; p.K1132K, 
c.3807 T>C; p.V1269V, c.5744 C>T; p.T1915M, c.7242 
A>G; p.S2414S, c.7806-14 T>C, c.8755-66 T>C, c.*105 
A>C), from which BRCA1 L771L and BRCA2 K1132K 
were those, carried only by a PaC affected family 
member.  
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IV.2.2. Six primary MMs  
No mutations were detected in the high-risk MM 
predisposing genes (CDKN2A, CDK4). We found some 
SNPs in CDKN2A (c.-191 G>A, c.*29 C>G) and she 
carried a MC1R ‘R’ variant (R151C).  
 
IV.2.3. MM and phenotype suggesting PHTS/CS  
No pathogenic mutation was detected along the examined 
genes, but she carried a number of SNPs in CDKN2A 
(IVS1β+174 A>G, c.*69 C>T), PTEN (c.80-96 A>G, 
c.1026+32 T>G), SDHB (c.18 C>A), SDHD genes 
(c.52+136 G>T, c.314+15 T>A) and a MC1R ‘R’variant 
(R160W), from which the alteration located in the IVS3 
of SDHD c.314+15 T>A is a new finding.  
V. CONCLUSIONS 
V.1. MPM study 
With this work, as a first study on Hungarian MPM 
patients from clinical, histologic and genetic point of 
view we can conclude, that 
1. The following results were in accordance with 
previous data from the literature:   
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 Rate of MPM occurrence among MM patients  
 Higher number of common nevi or presence of 
dysplastic naevus are susceptibility factors for MPM 
development 
 Younger age of onset in women than in men 
 Subsequent MMs in are thinner, more likely Mis than 
invasive MM, and develop commonly on the same 
body site with the first MM 
 Rate of CDKN2A mutations among MPM patients 
 Frequency of certain CDKN2A SNPs (c.*29 C>G, 
c.*69 C>T) 
 Frequency of MC1R non-synonymous variants 
 Frequency of ‘R’ variants  among MPM patients 
2. The following of our observations differed from 
previous reports, or brought novel results:  
 Less frequent positive family history of MM  
 A higher rate of synchronous first and second MMs  
 More frequent non-melanoma malignancy occurrence  
 Two Hungarian CDKN2A mutation carrier 
identification (p.E69G, p.R99P) 
 Lower frequency of CDKN2A A148T SNP 
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 Higher allele and carrier frequency of SNP CDKN2A 
c.-191 G>A 
 The MC1R R163Q variant to be exceptionally 
common among Hungarian MPM patients, a variant 
otherwise frequent in Asia, but not in Europe, 
supporting the previous findings on geographical 
differences regarding MC1R variant occurrence.  
 Identification of a new MC1R variant firstly in 
humans (c.350 A>G;p.D117G) 
 some new potentially unfavorable predictive 
observations among MC1R ‘R’ carriers compared to 
MC1R ‘r’ carriers 
 younger age of onset 
 MPM co-occurrence with more non-
melanoma primary tumors, or with multiple 
BCCs  
 more ulcerated first MMs, less ulcerated 
second MMs  
 TILs in second MMs (significantly). 
Therefore we hypothesize that as already suspected in 
terms of other MM predisposing genes (CDKN2A), 
MC1R genotype details may also carry additional useful 
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information concerning patient survival and prognosis if 
confirmed on bigger sample sizes.  
 
V.2. Unique MM-associated cases  
V.2.1. Two cancer prone families 
In family A, an unfavorable coincidence of inherited and 
environmental risk factors induced the new constellation 
of 4 primary malignancies (MPM, BCC, PrC, LC) in two 
non-twin siblings. In family B with a dominantly 
inherited PaC aggregation we could identify only a 
number of SNPs with unknown significance regarding 
PaC development. The inheritance of predisposing 
genetic events from the two families resulted in early 
onset malignant tumor formation in both of the offspring, 
in one of them even with fatal outcome. These data also 
indicate the relevance of identification of such cancer 
prone families and the necessity of a very close follow-up 
of the uninvolved family members too.  
 
V.2.2. Six primary MMs  
Despite the immunosuppressed state in the OTR patient, 
the development of six primary MMs raised the 
possibility of a genetic susceptibility to MM. in Besides 
18 
 
the skin tumor formations there was a complex interplay 
between diverse environmental (UV/sun tan habit; 
combined long term immunosuppression; bad 
compliance) and genetic (MC1R ‘R’ variant) 
predisposing factors. This case points out the importance 
of the careful dermatological follow up of OTRs under 
immunosuppressive therapy, and also of their education 
about the subsequent environmental predisposing factors.  
 
V.2.3. MM and phenotype suggesting PHTS/CS  
As a rare co-aggregation, MM with phenotype highly 
suspicious for PHTS/CS has been explored. However the 
involvement of a particular signal transduction pathway 
(PIP3K, PTEN, AKT1) and other genetic loci (SDHB, 
SDHD) were highly suspicious, we could not identify the 
exact underlying germline genetic disturbance. Analysis 
of AKT1 somatic mutations suspicious for Proteus 
syndrome, or next-generation techniques would be 
rational future options.  
In conclusions of the three Unique MM-associated 
cases we hypothesize the relevance of parallel inherited 
common gene alterations and gene-environment 
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interactions in malignant tumor development and 
aggregations. 
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